New Delhi, Oct. 29 -- A new artificial intelligence Nvidia-powered tool could help doctors assess the risk of breast cancer returning years before a recurrence occurs. SimBioSys, a precision medicine company, has received US Food and Drug Administration (FDA) clearance for TumorSight Risk, software that uses breast MRI scans, pathology and clinical data to estimate an individual patient's risk of cancer recurrence over five and 10 years.

The company describes TumorSight Risk as the world's first AI-powered, MRI-derived prognostic tool for assessing breast cancer recurrence risk. Designed to work with information already collected during routine care, the software aims to give oncologists additional insights to support treatment planning,...